PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7352116

Managing the epileptic patient.

E W Massey·W N Folger·T L Riley
View original source ↗Export metadata ↓

Abstract

A review of hospital charts revealed that only 3 (7.5%) of 40 inpatients with a diagnosis of epilepsy had received counseling about the disorder, its treatment, and its social ramifications. Although it is often neglected--as indicated by this small sample--proper and continuing patient education may dispel some of the damaging misconceptions and fears about the disorder and help the epileptic patient lead a full and productive life. Physicians should point out the importance of acceptance of the diagnosis, record keeping by the patient, awareness of precipitating factors, associated socioeconomic problems, and follow-up, stressing the possibility of normal life.

Explore related subjects

AnticonvulsantsAttitudeCivil RightsDrug TherapyEpilepsyHumansPatient CompliancePatient Education as TopicPatient ParticipationPrognosisRecordsSocioeconomic FactorsVoluntary Health AgenciesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E W Massey, W N Folger, T L Riley. 1980. Managing the epileptic patient.. https://doi.org/10.1080/00325481.1980.11715369

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗